Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label post-marketing observational study of Humira in Chinese children with polyarticular juvenile idiopathic arthritis
CTR20221019Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in juvenile idiopathic arthritis (JIA), sponsored by AbbVie Inc.. Started May 2022; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on CTR20221019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221019.